Jump to content

CC-1088

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by OAbot (talk | contribs) at 17:13, 1 January 2021 (Open access bot: doi added to citation with #oabot.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Skeletal formula

CC-1088 is a thalidomide analogue inhibitor of phosphodiesterase 4 that was being developed up to 2005 by Celgene Corp., for treating of inflammatory diseases and myelodysplastic syndromes.[1] Apremilast (CC-10004) was found to be a preferable.[2]

See also

References

  1. ^ K. Dredge (May 2005). "CC-1088 Celgene". Current Opinion in Investigational Drugs. 6 (5): 513–7. PMID 15912966.
  2. ^ Molostvov G, Morris A, Rose P, Basu S, Muller G (February 2004). "The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures". British Journal of Haematology. 124 (3): 366–75. doi:10.1046/j.1365-2141.2003.04777.x. PMID 14717786.
Retrieved from "https://en.wikipedia.org/w/index.php?title=CC-1088&oldid=997663910"